Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the sustained virologic response at post treatment
Week 12 for each cohort (BMS-790052/Pegylated-interferon alfa 2a (pegIFNα-2a)/Ribavirin (RBV)
versus placebo/PegIFNα-2a/RBV).